Novo Nordisk A/S (NONOF)
| Market Cap | 493.25B |
| Revenue (ttm) | 37.07B |
| Net Income (ttm) | 12.92B |
| Shares Out | n/a |
| EPS (ttm) | 2.89 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 0.52 (0.44%) |
| Ex-Dividend Date | Aug 15, 2024 |
| Volume | 300 |
| Open | 112.00 |
| Previous Close | 112.00 |
| Day's Range | 112.00 - 113.15 |
| 52-Week Range | 93.80 - 149.55 |
| Beta | 0.15 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2024 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]
Financial Performance
In 2023, Novo Nordisk's revenue was 232.26 billion, an increase of 31.26% compared to the previous year's 176.95 billion. Earnings were 83.68 billion, an increase of 50.71%.
Financial numbers in DKK Financial StatementsNews
Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 28 October 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates
SAN FRANCISCO--(BUSINESS WIRE)--Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates.
Could Buying This Weight Loss Stock Be Like Investing in Novo Nordisk At The Dawn of The GLP-1 Revolution?
Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.
This Is Huge News for Novo Nordisk (Hint: It Doesn't Involve Ozempic)
Novo Nordisk just released data from a clinical trial featuring its oral semaglutide treatment, Rybelsus.
Ozempic Can Potentially Cut Risk Of Alzheimer's Compared To Other Diabetic Medicines, Study Shows
Researchers at Case Western Reserve University School of Medicine have discovered that Novo Nordisk A/S’ (NYSE: NVO) semaglutide, an ingredient for a well-known diabetes and weight-loss drug, may red...
Novo Nordisk's semaglutide could also be effective against Alzheimer's
Study finds GLP-1 drugs like semaglutide may reduce Alzheimer's risk for diabetes patients. Read more here.
Lilly to launch Mounjaro in rival Novo Nordisk's home country: report
Lilly to launch its obesity drug in Denmark, Novo Nordisk's home market
Lilly will launch its Mounjaro obesity drug in Denmark next week, the U.S. drugmaker said on Thursday, bringing competition to the home country of its biggest weight-loss rival, Danish pharmaceuticals...
Novo Nordisk's diabetes drug Ozempic may reduce the risk of Alzheimer's disease, study says
The active ingredient in Ozempic was associated with a 40% to 70% lower risk of a first-time Alzheimer's diagnosis in diabetes patients.
Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
Novo Nordisk (NYSE: NVO) has appealed to the U.S. Food and Drug Administration (FDA) to halt the production of compounded versions of its drugs Wegovy and Ozempic by compounding pharmacies. These che...
Who Will Dominate the Future of Pharmaceutical Industries in 2030?
Dear reader, market forecasts for 2030 indicate a significanttransformation in the global pharmaceutical landscape, with several leading companies, including Novo Nordisk and Eli L...
Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copy-cats
Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own versions of the company’s popular weight loss drug Wegovy and diabetes treatmen...
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-21796315191-2b5118fea284401782bbeed939c092bc.jpg)
Nvidia Launches Danish Sovereign AI Supercomputer That Novo Nordisk Will Use
Pharmaceutical giant Novo Nordisk plans to use Denmark's first sovereign artificial intelligence supercomputer—powered by Nvidia technology—for drug discovery.
Healthy Returns: Weight loss, diabetes drugs may reduce alcohol and opioid use
GLP-1 drugs such as Novo Nordisk's Ozempic can cut drug and alcohol abuse by around half. Meanwhile, tech companies are talking the future of AI in health care.
Novo Nordisk asks US to stop compounding pharmacies from making weight-loss drug copies
Novo Nordisk on Tuesday asked the U.S. Food and Drug Administration to ban compounding pharmacies from making copycat versions of its popular weight-loss and diabetes drugs, which it said were too com...
Novo Nordisk's Death Cross: Is A Turnaround Coming For The Ozempic, Wegovy Maker?
Novo Nordisk A/S (NYSE: NVO) just hit a technical red flag — a Death Cross . Chart created using Benzinga Pro For those uninitiated, this bearish signal occurs when a stock's 50-day moving average dr...
Novo Nordisk's Death Cross: Is A Turnaround Coming For The Ozempic, Wegovy Maker?
Novo Nordisk A/S NVO just hit a technical red flag — a Death Cross.
Novo Nordisk asks FDA to ban compounding pharmacies from making Ozempic, Wegovy copies
The Danish drugmaker Novo Nordisk argues that semaglutide, the active ingredient in Ozempic and Wegovy, are too complex for those manufacturers to make safely.
Thermo Fisher Scientific Sails Through Q3 With Mixed Earnings, CEO Says In Great Position To Deliver 2024 Objectives
On Wednesday, Thermo Fisher Scientific Inc. (NYSE: TMO) posted third-quarter revenue of $10.59 billion, almost flat year over year, marginally missing the consensus of $10.64 billion . Revenue growth,...
Danes to Use New Nvidia AI Supercomputer for Drug Discovery
Denmark unveiled an Nvidia-powered supercomputer that will be used by Novo Nordisk A/S and other Danish pharmaceutical companies as they seek novel drugs and smarter trial designs.
Viking Therapeutics Stock Up 240% YTD: Can Q3 Earnings, Weight-Loss Drug Drive Further Gains?
Viking Therapeutics Inc. (NASDAQ: VKTX) is set to report its third-quarter earnings on Wednesday, after the market closes. The anticipation is palpable, especially as the stock has skyrocketed almost...
Novo Nordisk: Be Cautious About Buying The Dip
Dr. Scot Gottlieb on Novo Nodrisk's oral diabetes drug, future of weight-loss drugs
Former FDA Commissioner Dr. Scot Gottlieb joins 'Squawk Box' to discuss news of Novo Nordisk's oral diabetes drug cutting heart-related risks in patients, state of the weight-loss drugs market, and mo...
Dr. Scot Gottlieb on Novo Nodrisk's oral diabetes drug, future of weight-loss drugs
Former FDA Commissioner Dr. Scot Gottlieb joins 'Squawk Box' to discuss news of Novo Nordisk's oral diabetes drug cutting heart-related risks in patients, state of the weight-loss drugs market, and mo...
Eli Lilly Sues Some Vendors For Unauthorized Sale Of Fake Weight-Loss Drug
Eli Lilly And Co (NYSE: LLY) has reportedly sued some medical spas and online vendors for allegedly selling unauthorized versions of tirzepatide, the active ingredient in its weight-loss medication, ...